Press & News

People are different and so is their cancer, patients should be treated individually.

Invitation to 2cureX webcast and conference call on November 24, 2022

November 22, 2022

IR

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, will publish its Q3 2022 report on Thursday November 24, 2022 at 8:30 CET.

 
2cureX will host a webcast on the same day at 10:00 CET and present its Q3 results. After the presentation there will be a Q&A session at which 2cureX’s Executive Management will answer any questions to the Q3 reporting and to the Strategy Deep-Dive held on November 15, 2022.

To join the webcast, simply click here: https://www.2curex.com/2curex-webinar-q3-2022/

For editors and the press

For more information, please contact:

Fernando Andreu
Chief Executive Officer
fa@2curex.com